Acute inflammation is visible, purposeful, and self-limiting. Chronic inflammation is none of those things. It operates below the threshold of obvious symptoms, produces no fever, no obvious swelling, and no clear diagnosis — until it does, in the form of cardiovascular disease, type 2 diabetes, neurodegenerative pathology, autoimmune conditions, and a growing list of clinical entities that share chronic inflammatory dysregulation as a common upstream driver.
How chronic inflammation presents in high performers
In high-functioning individuals without a formal diagnosis, chronic inflammation tends to present as a cluster of non-specific functional complaints: persistent fatigue that does not resolve with rest, cognitive inconsistency, mood instability in the context of otherwise adequate sleep and nutrition, frequent minor infections, longer recovery time from physical exertion, and a gradual reduction in the ceiling of what is tolerable or achievable. These complaints are frequently dismissed as 'stress' or 'getting older.' They are clinical signals.
What chronic inflammation actually feels like
Patients rarely describe their presentation as 'inflammation.' They describe: waking up tired despite adequate sleep, a sense of mental fog that coffee helps temporarily but does not resolve, recovery from exercise that feels slower than it used to, and a vague awareness that something is off despite clean lab results on the standard annual panel. Standard labs do not include hsCRP, IL-6, or a gut permeability assessment. That is why these presentations go undiagnosed.
The drivers worth identifying
- Intestinal permeability and dysbiosis — the most modifiable inflammatory driver in most adults
- Chronic psychological stress — drives sustained cortisol elevation and downstream immune dysregulation
- Dietary pattern — ultra-processed food drives inflammatory gene expression independent of calorie intake
- Sleep disruption — a single night of poor sleep produces measurable increases in inflammatory markers
- Environmental toxin burden — persistent organic pollutants and heavy metals drive chronic immune activation
- Visceral adiposity — adipose tissue is immunologically active and produces pro-inflammatory cytokines
Clinical evidence — New England Journal of Medicine, 2008
Among 17,802 apparently healthy adults with LDL below 130 mg/dL but hsCRP above 2 mg/L, rosuvastatin reduced hsCRP by 37% and major cardiovascular events by 44% — establishing elevated hsCRP as an independent cardiovascular risk marker and confirming that targeting inflammation, not just lipids, changes clinical outcomes.
Ridker PM et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine (JUPITER Trial).
Inflammation is not the disease. It is the body's response to a signal it cannot resolve. The clinical question is always: what is the signal that is not resolving?
What to measure
High-sensitivity C-reactive protein (hsCRP) is the most broadly useful clinical marker for chronic low-grade inflammation. An hsCRP below 1.0 mg/L represents low cardiovascular and inflammatory risk; values between 1.0 and 3.0 indicate intermediate risk; above 3.0 indicates elevated risk. Erythrocyte sedimentation rate (ESR), interleukin-6, and homocysteine provide additional information in specific clinical contexts. The inflammatory marker panel should always be interpreted alongside the full clinical picture, not in isolation.
| hsCRP Level | Risk Category | Cardiovascular Implication | Clinical Action |
|---|---|---|---|
| < 0.5 mg/L | Optimal | Lowest documented risk | Maintain with lifestyle optimisation |
| 0.5–1.0 mg/L | Low | Low cardiovascular risk | Annual monitoring; address modifiable drivers |
| 1.0–3.0 mg/L | Intermediate | 2× cardiovascular event risk vs < 1.0 | Clinical investigation of drivers; dietary and lifestyle intervention |
| > 3.0 mg/L | Elevated | 3× cardiovascular event risk vs < 1.0 | Immediate clinical investigation; exclude acute infection before interpreting |
| > 10 mg/L | High / Acute | May indicate acute infection or injury | Repeat in 2 weeks; exclude acute cause before chronic management |
The integrative clinical response
Addressing chronic inflammation is not primarily a pharmaceutical problem. The most powerful anti-inflammatory interventions available — dietary pattern change, gut microbiome restoration, sleep optimisation, stress physiology regulation, and targeted botanical medicine — are lifestyle and clinical tools. Pharmaceutical anti-inflammatories have their place in acute management and specific pathologies, but they do not address the drivers that sustain chronic inflammatory activation. The integrative approach does.
The integrative anti-inflammatory protocol — priority order
- Gut restoration first: intestinal permeability is the most common and most modifiable inflammatory driver. Remove the trigger before adding the intervention.
- Dietary pattern change: Mediterranean pattern reduces hsCRP by 20–30% in most adults over 12 weeks — comparable to low-dose statin therapy.
- Sleep optimisation: 7.5–9 hours of quality sleep reduces inflammatory markers more reliably than most supplements.
- Targeted botanicals: curcumin, boswellia, and omega-3 at therapeutic doses have Level 1 evidence for reducing hsCRP and inflammatory cytokines.
- Stress physiology: HRV-guided autonomic training reduces IL-6 and cortisol — the two hormonal drivers that sustain inflammatory activation.
